Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source
No articles found.
Check-Cap is a clinical-stage medical diagnostics company developing C-ScanÂŽ, the...
Check-Cap is a clinical-stage medical diagnosti...
Anthera Pharmaceuticals, Inc., a development stage biopharmaceutical company, focu...
Anthera Pharmaceuticals, Inc., a development st...
Eliot's produces peanut and nut butters featuring US grown nuts based in Portland ...
Eliot's produces peanut and nut butters featuri...
Crinetics is a clinical stage pharmaceutical company focused on the discovery, dev...
Crinetics is a clinical stage pharmaceutical co...
Cue Biopharma is an innovative clinical stage immunotherapy company developing a n...
Cue Biopharma is an innovative clinical stage i...
PhorMed is a clinical stage biopharmaceutical company located in Beverly Hills Cal...
PhorMed is a clinical stage biopharmaceutical c...
Based in South San Francisco, we are a clinical-stage biotechnology company commit...
Based in South San Francisco, we are a clinical...
Join the National Investor Network and get the latest information with your interests in mind.